# Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

> **NCT02318602** · PHASE3 · COMPLETED · sponsor: **INSYS Therapeutics Inc** · enrollment: 52 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Cannabidiol Oral Solution

## Key facts

- **NCT ID:** NCT02318602
- **Lead sponsor:** INSYS Therapeutics Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-08
- **Primary completion:** 2017-06-22
- **Final completion:** 2017-06-22
- **Target enrollment:** 52 (ACTUAL)
- **Last updated:** 2018-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02318602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02318602, "Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02318602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*